|Description||Automated Multiplexing MDx Solution|
|Series C, 3/2007 ||$12M|
|Seed, 1/2013 ||$166k|
AutoGenomics, Inc., a privately held company based in Vista, CA has developed one of the first automated microarray based multiplexing molecular diagnostic platforms that can be used to assess disease signatures with novel genetic biomarkers in the areas of womenâ€™s health, cancer and personalized medicine. With discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to a new era of personalized medicine.